Biotech

All Articles

Analysts explore Avidity's DMD win, exposing distinctions in data

.Avidity Biosciences impressed financiers with stage 1/2 information in Duchenne muscle dystrophy (D...

Actinogen's cortisol blocker falls short stage 2 clinical depression research study

.Actinogen Medical's cortisol blocker has actually overlooked the primary endpoint of a period 2 res...

Bivictrix makes a decision going private only way to take ADC into center

.Antibody-drug conjugates (ADCs) have been at the center of a lot of a billion-dollar biobuck licens...

TPG leadings up funds to $580M for assets all over lifestyle scientific researches

.Asset manager TPG, which has assisted biotechs including Sionna Rehabs and also Santa Clam Ana Bio,...

Merck quits period 3 TIGIT trial in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT system has gone through one more drawback. Months after shuttering a period ...

After a difficult year, Exscientia folds in to Recursion

.After a year determined by pipe cuts, the shift of its own CEO as well as layoffs, Exscientia will ...

Cullinan, after $25M package, return bispecific to Port

.Cullinan Rehab was actually made an impression on good enough with Port BioMed's bispecific invulne...

A better check out Fierce Biotech's Fierce 15

.In this particular week's incident of "The Best Line," our team're diving right into Intense Biotec...

Lilly experiences period 2 failure of tau-targeting med

.The confetti is still flying coming from Eli Lilly's gathering celebrating the commendation of Alzh...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, firings ...